Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Vaccsyn Biotech Pvt Ltd

    Vaccsyn Biotech Pvt Ltd incorporated in 2007, is a Thane-based company engaged in the manufacture of anti-snake venom serum, anti-tetanus serum and anti-rabies serum. The compan

  • No Image
    Vamso Biotec Pvt Ltd

    Vamso Biotec Pvt Ltd is engaged in production of Natural, Biotechnological and Allopathic products for health & productivity needs of variety of animal species through its grou

  • No Image
    Vanan Pharma Pvt Ltd

    Vanan Pharma Pvt Ltd was incorporated in the year 2002 and is engaged in the business of manufacturing oral liquid products & paracetamol products. The company is promoted by Mr

  • No Image
    Vardhman Life Sciences Pvt Ltd

    Vardhman Life Sciences Pvt Ltd has been promoted by Vardhman Chemtech Ltd and Mr Sushil Kumar Singla who hold 51% and 49% stake respectively. VLSPL was originally incorporated